Journal Article (Review Article)

DKFZ-2022-03087

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Circulating tumour cells in patients with lung cancer universally indicate poor prognosis.

Jin, F. (First author)DKFZ* ; Zhu, L. (First author)DKFZ* ; Shao, J. ; Yakoub, M.DKFZ* ; Schmitt, L.DKFZ* ; Reißfelder, C. ; Loges, S.DKFZ* ; Benner, A.DKFZ* ; Schölch, S. (Last author)DKFZ*

2022
Soc. Sheffield

This record in other databases:  

Please use a persistent id in citations: doi:10.1183/16000617.0151-2022

Abstract: In lung cancer, the relevance of various circulating tumour cell (CTC) subgroups in different lung cancer subtypes is unclear. We performed a comprehensive meta-analysis to assess the prognostic value of CTCs in the different histological types of lung cancer, with particular respect to CTC subtypes, cut-offs and time points of CTC enumeration.We searched MEDLINE, Web of Science and Embase alongside relevant studies evaluating the prognostic value of CTCs in lung cancer patients. A random-effects model was used for meta-analysis, calculating hazard ratios (HRs), 95% confidence intervals and p-values.27 studies enrolling 2957 patients were included. CTC detection indicates poor prognosis, especially in small cell lung cancer (SCLC) patients (overall survival HR 3.11, 95% CI 2.59-3.73) and predicts a worse outcome compared to nonsmall cell lung cancer patients. Epithelial CTCs predict a worse outcome for lung cancer than mesenchymal CTCs or epithelial-mesenchymal hybrids.CTCs indicate poor prognosis in patients with primary lung cancer, with CTCs in SCLC having a more pronounced prognostic effect. The prognostic value of CTCs detected by different markers varies; most evidence is available for the strong negative prognostic effect of epithelial CTCs.

Keyword(s): Humans (MeSH) ; Neoplastic Cells, Circulating: pathology (MeSH) ; Lung Neoplasms: pathology (MeSH) ; Carcinoma, Non-Small-Cell Lung (MeSH) ; Prognosis (MeSH) ; Biomarkers, Tumor (MeSH) ; Biomarkers, Tumor

Note: #EA:A430#LA:A430#

---

Contributing Institute(s):

1. NWG-KKE Translationale Chirurgische Onkologie (A430)
2. Personalisierte Medizinische Onkologie (A420)
3. C060 Biostatistik (C060)

Research Program(s):

1. 311 - Zellbiologie und Tumorbiologie (POF4-311) (POF4-311)

Appears in the scientific report 2022

---

Database coverage:
; ; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Essential Science Indicators ; IF >= 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---